Table 2 Average dosimetric data and plan evaluation parameters for rectum and bladder
From: Passive proton therapy vs. IMRT planning study with focal boost for prostate cancer
V90 | p* | V75< 15 %b | p* | V70< 25 %b | p* | V65< 35 %b | p* | V60< 50 %b | p* | D mean a | p* | ID c | p* | ID c (w) | p* | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rectum (w = wall) | Proton | 1.1 % | 0.315 | 6.7 % | 0.631 | 9.7 % | 0.315 | 12.3 % | 0.029 | 14.6 % | 0.009 | 21.5 | <0.001 | 50.1 | <0.001 | 15.2 | <0.001 |
IMRT | 0.7 % | 7.3 % | 11.4 % | 15.7 % | 20.4 % | 38.9 | 92.1 | 25.7 | |||||||||
Bladder (w = wall) | V90 | p* | V80< 15 %b | p* | V75< 25 %b | p* | V70< 35 %b | p* | V65< 50 %b | p* | D mean a | p* | ID c | p* | ID c (w) | p* | |
Proton | 2.8 % | 0.089 | 8.1 % | 0.035 | 10.0 % | 0.075 | 12.1 % | 0.165 | 14.1 % | 0.218 | 19.7 | 0.190 | 60.6 | 0.043 | 21.1 | 0.052 | |
IMRT | 1.7 % | 5.0 % | 6.7 % | 8.6 % | 10.5 % | 24.5 | 82.9 | 25.7 |